 JUPITER, Fla., March 31, 2021 PRNewswire -- Marizyme, Inc. OTCQB: MRZM, a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, and other surgical indications, announces that Board Chairman James Sapirstein has issued a Letter to Shareholders providing a business update for the Companys recent activities. 